Globalspace Technologies is a digital health company that builds software platforms for India’s pharmaceutical industry - connecting doctors, pharmacies, distributors and sales teams on a single digital backbone. It was founded in 2010 by Krishna Murari Singh, a pharma and healthcare veteran who started the company to lead India’s digital healthcare market, but diversified into education technology in its early years because the health-tech market was still incipient. The recurring approach is to build integrated software-product platforms as long-term intellectual property, then embed them deep inside pharma companies’ sales and marketing workflows - so the platform becomes the operating system for how medicines reach patients. # Business segments Three engines at different stages - a health-platforms core that now generates nearly all revenue, a contract sales-force unit bought to cross-sell into pharma clients, and a former education business reduced to a minority investment - each reflecting the company’s pivot back to its founding healthcare mission. ## 1. Digital health platforms: the operating system for pharma sales and distribution **A suite of interconnected software platforms that digitise every link in the pharmaceutical chain - from the sales rep’s tablet to the doctor’s prescription pad to the chemist’s shelf - earning subscription fees, commissions and analytics revenue at each step.** - **A platform for every player in the chain** - DocExa gives doctors a virtual clinic with appointment scheduling, e-prescriptions and video consultations; Mediapp (now MediOla) is a B2B e-commerce marketplace connecting pharma distributors with over 45,000 retailers and 800 stockists; Vodo arms sales representatives with closed-loop marketing and sales-force automation tools on a single tablet. Together they form what the company calls “probably the only truly integrated digital health platform” covering doctors, pharmacies, distributors and salespeople in one system. - **Paid per doctor, per rep, per transaction** - DocExa charges a monthly subscription per doctor plus a cut of each consultation fee, and sells anonymised prescribing data back to pharma companies; Mediapp earns commission on every transaction flowing through its distributor-to-retailer marketplace; Vodo runs on a per-representative-per-month SaaS model. That means revenue grows with usage, not just with new sign-ups. - **Pfizer on the platform** - in early 2021 the company signed a non-exclusive alliance with Pfizer to build virtual adult-vaccine consultation clinics on DocExa, with a custom booking tab on Pfizer’s consumer website redirecting patients straight to DocExa’s e-consultation page. The deal started with one vaccine and had scope to expand across Pfizer’s entire portfolio, giving the platform a stamp of credibility that helped attract other large pharma accounts. - **An AI layer on top** - in late 2025 Globalspace launched PATGPT, a large language model trained specifically on pharmaceutical datasets, half on the company’s own data and half inside each pharma client’s secure cloud environment. It starts with sales, marketing and inventory optimisation, with a roadmap stretching into R&D and clinical trials - turning the platforms from workflow tools into intelligence engines. - **The subsidiary that runs the marketplace** - the MediOla platform sits inside Miljon Medi App Private Limited, originally an LLP in which Globalspace took a 5% stake in 2020 and which it converted into a 99.83% subsidiary by mid-2026 after converting a INR 12.64 crore loan into equity. That structure lets the marketplace business scale with its own focus while Globalspace consolidates the economics. ## 2. Contract sales force: feet on the street for pharma companies **A 51%-owned subsidiary that puts sales representatives in the field for pharmaceutical companies - a people-intensive service that gives Globalspace a direct channel to sell its digital platforms into the same client base.** - **Bought, not built** - Globalspace acquired its controlling stake in Innopharm Healthcare Private Limited in 2024 for INR 51 lakhs in cash, after the board recognised that Innopharm’s client relationships would open doors for Globalspace’s own pharma software products. - **Cross-sell logic** - the acquisition was explicitly described as a strategic fit because Globalspace already helps pharma companies augment their sales and marketing efforts digitally; owning a physical sales-force unit means it can offer clients a combined physical-plus-digital package. ## 3. STEAM education: a former growth engine now reduced to a minority stake **What was once the company’s second-largest revenue stream - a robotics and coding education business for schools - was largely exited in 2022, leaving only a residual investment.** - **Built for schools, sold through partners** - Makebot provided a full 360-degree solution: STEAM lab setups, DIY robotics kits for children aged six and up, in-school curriculum, a digital academy, and train-the-trainer programmes for teachers. By early 2021 it had over 1,200 schools on its platform and had signed international partnerships with seven partners across six countries including Malaysia, Singapore and Australia. - **Residual value** - as of March 2025 Globalspace still holds 38,323 shares in Makebot, classified as a financial investment rather than an operating business. It is a legacy position, not an active growth engine. # Group structure and partners **A listed parent with two operating subsidiaries - one for digital pharma marketplaces, one for physical sales forces - and a founder-promoter who holds majority control.** - The promoter and promoter group held 55.84% of Globalspace as of March 2025, with founder Krishna Murari Singh as Chairman and Managing Director and his spouse Beauty Kumari Singh on the board as a non-executive director. - Miljon Medi App Private Limited, the 99.83%-owned subsidiary housing the MediOla marketplace, was converted from an LLP in March 2025 and recapitalised through a INR 12.64 crore debt-to-equity conversion. - Strategic health-tech partners have included Pfizer (for vaccine e-consultations on DocExa), Cadila and Macleods. The company’s AI screening initiative in Maharashtra involves a non-equity partnership with Australia’s MOD3RN Care and GE Healthcare for hardware, with a 60:40 profit split in the initial state rollout.